## Michael Voulgarelis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6959323/publications.pdf

Version: 2024-02-01

257450 168389 2,903 62 24 53 citations g-index h-index papers 62 62 62 3142 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Clinical picture, outcome and predictive factors of lymphoma in primary Sjögren's syndrome: results from a harmonized dataset (1981–2021). Rheumatology, 2022, 61, 3576-3585.	1.9	19
2	Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3): A Novel Marker for Lymphoma Development among Patients with Young Onset Sjogren's Syndrome. Journal of Clinical Medicine, 2021, 10, 644.	2.4	7
3	Effects of Visceralising Leishmania on the Spleen, Liver, and Bone Marrow: A Pathophysiological Perspective. Microorganisms, 2021, 9, 759.	3.6	18
4	Exploiting the Role of Hypoxia-Inducible Factor 1 and Pseudohypoxia in the Myelodysplastic Syndrome Pathophysiology. International Journal of Molecular Sciences, 2021, 22, 4099.	4.1	3
5	From the (Epi)Genome to Metabolism and Vice Versa; Examples from Hematologic Malignancy. International Journal of Molecular Sciences, 2021, 22, 6321.	4.1	5
6	Lipoprotein-Associated Phospholipase A2: A Novel Contributor in Sjögren's Syndrome-Related Lymphoma?. Frontiers in Immunology, 2021, 12, 683623.	4.8	6
7	+3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with Sjögren's Syndrome: Potential Clinical and Pathogenetic Implications. Journal of Clinical Medicine, 2021, 10, 3960.	2.4	5
8	Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren's Syndrome. Frontiers in Immunology, 2021, 12, 705079.	4.8	8
9	Interferon (IFN)-stimulated gene 15: A novel biomarker for lymphoma development in Sjögren's syndrome. Journal of Autoimmunity, 2021, 123, 102704.	6.5	9
10	Akt Signaling Pathway Is Activated in the Minor Salivary Glands of Patients with Primary Sjögren's Syndrome. International Journal of Molecular Sciences, 2021, 22, 13441.	4.1	1
11	TREX1 variants in Sjogren's syndrome related lymphomagenesis. Cytokine, 2020, 132, 154781.	3.2	18
12	Bioenergetic Profiling of the Differentiating Human MDS Myeloid Lineage with Low and High Bone Marrow Blast Counts. Cancers, 2020, 12, 3520.	3.7	9
13	Pathogenetic Mechanisms Implicated in Sjögren's Syndrome Lymphomagenesis: A Review of the Literature. Journal of Clinical Medicine, 2020, 9, 3794.	2.4	16
14	Extraordinary extrahaematological manifestations of chronic myelomonocytic leukaemia. Lancet, The, 2020, 396, 853.	13.7	2
15	Leishmaniasis with cryoglobulinaemia and <i>Leishmania infantum</i> in peripheral blood neutrophils. British Journal of Haematology, 2020, 189, 801-801.	2.5	3
16	Lymphoma Severity and Type Are Associated With Aortic FDG Uptake by 18F-FDG PET/CT Imaging. JACC: CardioOncology, 2020, 2, 758-770.	4.0	5
17	The Metabolomic Status of the Differentiating Myeloid Lineage in MDS with Low and High Bone Marrow Blast Counts. Blood, 2020, 136, 32-33.	1.4	1
18	Response to: â€~ls miR200b-5p a new predictor of lymphoma or associated with lymphocytes infiltrate within salivary glands?' by Nocturne et al. Annals of the Rheumatic Diseases, 2019, 78, e96-e96.	0.9	0

#	Article	IF	Citations
19	Predictive markers of lymphomagenesis in Sj $\tilde{A}$ <b>g</b> ren's syndrome: From clinical data to molecular stratification. Journal of Autoimmunity, 2019, 104, 102316.	6.5	36
20	AB0527â€PREDICTIVE VALUE OF MIR200B-5P IN THE LYMPHOMAGENESIS IN SJÃ-GREN'S SYNDROME (SS) COMPARISON WITH THE PUBLISHED PREDICTION MODELS. PRELIMINARY RESULTS. , 2019, , .	:	0
21	SATO190â€LYMPHOMA IN PRIMARY SJÃ-GREN'S SYNDROME: A RETROSPECTIVE CLINICAL STUDY WITH PAFROM THE UPA (UDINE, PISA, ATHENS) GROUP. , 2019, , .	TIENTS	0
22	TNFAIP3 F127C Coding Variation in Greek Primary Sjogren's Syndrome Patients. Journal of Immunology Research, 2018, 2018, 1-8.	2.2	24
23	Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with Sjögren's syndrome. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212639.	0.9	32
24	Autophagy in Myelodysplastic Syndromes: The Role of HIF-1a/REDD1 Molecular Pathway. Blood, 2018, 132, 1808-1808.	1.4	4
25	MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome. Scientific Reports, 2017, 7, 7354.	3.3	28
26	07.08â€Contribution of mthfr gene polymorphisms in primary sjögren's syndrome related lymphomagenesis. , 2017, , .		0
27	08.16â€Mir200B-5p expression in minor salivary glands (msg): a possible predictor of lymphoma development in sjögren's syndrome (ss). , 2017, , .		O
28	Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. Haematologica, 2015, 100, e446-e449.	3.5	44
29	A BAFF Receptor His159Tyr Mutation in Sjögren's Syndrome–Related Lymphoproliferation. Arthritis and Rheumatology, 2015, 67, 2732-2741.	5.6	60
30	Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis. Journal of Autoimmunity, 2015, 63, 47-58.	6.5	215
31	Predicting the Outcome of Sjogren's Syndrome-Associated Non-Hodgkin's Lymphoma Patients. PLoS ONE, 2015, 10, e0116189.	2.5	77
32	Clinical picture, outcome and predictive factors of lymphoma in SjÓ§gren syndrome. Autoimmunity Reviews, 2015, 14, 641-649.	5.8	68
33	Predicting progression to lymphoma in Sjögren's syndrome patients. Expert Review of Clinical Immunology, 2014, 10, 501-512.	3.0	26
34	A comprehensive review of myelodysplastic syndrome patients with autoimmune diseases. Expert Review of Clinical Immunology, 2014, 10, 1679-1688.	3.0	9
35	B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. Journal of Autoimmunity, 2014, 51, 89-98.	6.5	99
36	Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology, 2014, 53, 2209-2213.	1.9	67

#	Article	IF	CITATIONS
37	Malignant lymphoma in primary Sjögren's syndrome: An update on the pathogenesis and treatment. Seminars in Arthritis and Rheumatism, 2013, 43, 178-186.	3.4	63
38	Inheritance and Myelodysplasia progression. Leukemia Research, 2013, 37, 1185-1186.	0.8	1
39	Prognosis and Outcome of Non-Hodgkin Lymphoma in Primary Sjögren Syndrome. Medicine (United) Tj ETQq1 I	1 0.78431 1.0	4 rgBT /Over
40	<i>GSTT1</i> and <i>GSTM1</i> polymorphisms and myelodysplastic syndrome risk: a systematic review and metaâ€analysis. International Journal of Cancer, 2010, 126, 1716-1723.	5.1	17
41	Bone marrow necrosis and fat embolism syndrome presented as conus medullaris syndrome in a patient with primary mediastinal large B-cell lymphoma. Leukemia Research, 2010, 34, 116-118.	0.8	4
42	Current aspects of pathogenesis in Sjögren's syndrome. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 325-334.	2.7	31
43	Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. Nature Reviews Rheumatology, 2010, 6, 529-537.	8.0	206
44	Aplastic anemia associated with interferon alpha 2a in a patient with chronic hepatitis C virus infection: a case report. Journal of Medical Case Reports, 2010, 4, 268.	0.8	17
45	Hematologic Manifestations and Predictors of Lymphoma Development in Primary Sjögren Syndrome. Medicine (United States), 2009, 88, 284-293.	1.0	233
46	Mucosa-Associated Lymphoid Tissue Lymphoma in Sjögren's Syndrome: Risks, Management, and Prognosis. Rheumatic Disease Clinics of North America, 2008, 34, 921-933.	1.9	69
47	No Evidence for Increased Prevalence of JAK2 V617F in Women with a History of Recurrent Miscarriage. Blood, 2008, 112, 5235-5235.	1.4	0
48	Cardiac Magnetic Resonance Imaging Detects Long-Term Fibrotic Changes in Patients with Primary Eosinophilic Disorders: A Cross-Sectional Study. Blood, 2008, 112, 5236-5236.	1.4	0
49	Toll-like Receptor-4 Is Up-Regulated in Hematopoietic Progenitor Cells and Contributes to Increased Apoptosis in Myelodysplastic Syndromes. Clinical Cancer Research, 2007, 13, 1154-1160.	7.0	124
50	RNA Interference of Interferon Regulatory Factor-1 Gene Expression in THP-1 Cell Line Leads to Toll-Like Receptor-4 Overexpression/Activation As Well As Up-modulation of Annexin-II. Neoplasia, 2007, 9, 1012-1020.	5.3	15
51	GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34+ and erythroid CD71+ cells in myelodysplastic syndromes. American Journal of Hematology, 2007, 82, 887-892.	4.1	10
52	Clinical, Immunologic, and Molecular Factors Predicting Lymphoma Development in Sjogren's Syndrome Patients. Clinical Reviews in Allergy and Immunology, 2007, 32, 265-274.	6.5	67
53	Suspects in the tale of lupus-associated thrombocytopenia. Clinical and Experimental Immunology, 2006, 145, 71-80.	2.6	40
54	Aberrant alternative splicing of interferon regulatory factor-1 (IRF-1) in myelodysplastic hematopoietic progenitor cells. Leukemia Research, 2006, 30, 1177-1186.	0.8	17

#	Article	IF	CITATION
55	Bone marrow histological findings in systemic lupus erythematosus with hematologic abnormalities: A clinicopathological study. American Journal of Hematology, 2006, 81, 590-597.	4.1	67
56	Effect of cA2 Anti–Tumor Necrosis Factor-α Antibody Therapy on Hematopoiesis of Patients with Myelodysplastic Syndromes. Clinical Cancer Research, 2006, 12, 3099-3108.	7.0	24
57	Simultaneous occurrence of pure red cell aplasia and papular-purpuric 'gloves and socks' syndrome in parvovirus B-19 infection. Journal of the European Academy of Dermatology and Venereology, 2005, 19, 373-376.	2.4	10
58	Myelofibrosis-associated massive splenomegaly: A cause of increased intra-abdominal pressure, pulmonary hypertension, and positional dyspnea. American Journal of Hematology, 2005, 80, 128-132.	4.1	18
59	The Risk of Lymphoma Development in Autoimmune Diseases. Archives of Internal Medicine, 2005, 165, 2337.	3.8	647
60	Myelodysplasiaâ€associated autoimmunity: clinical and pathophysiologic concepts. European Journal of Clinical Investigation, 2004, 34, 690-700.	3.4	84
61	Autoimmune manifestations in common variable immunodeficiency. Clinical Rheumatology, 2004, 23, 449-452.	2.2	25
62	Membranous glomerulonephritis in chronic lymphocytic leukemia. American Journal of Hematology, 2004, 76, 271-274.	4.1	16